Patents by Inventor Wilfried Dalemans

Wilfried Dalemans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mesenchymal stem cell-derived exosomes and their uses
    Patent number: 11857575
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 2, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • Lymphocyte biomarkers for determining the clinical response to cell therapy
    Patent number: 11478511
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: October 25, 2022
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans
  • MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS
    Publication number: 20200376038
    Abstract: The invention relates to the use of mesenchymal stromal cells (MSCs) for treating sepsis in a subject. The invention provides compositions, uses and methods for the treatment of sepsis.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 3, 2020
    Applicant: TiGenix, S.A.U.
    Inventors: Wilfried DALEMANS, Eleuterio LOMBARDO, Robert DEKKER
  • LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY
    Publication number: 20200261511
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 20, 2020
    Inventors: Olga DE LA ROSA, Eleuterio LOMBARDO, Wilfried DALEMANS
  • Biomarkers for determining the clinical response to cell therapy
    Patent number: 10746729
    Abstract: The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 18, 2020
    Assignee: TIGENIX, S.A.U.
    Inventors: Olga De La Rosa, Wilfried Dalemans
  • Lymphocyte biomarkers for determining the clinical response to cell therapy
    Patent number: 10660920
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 26, 2020
    Assignees: TIGENIX NV, TIGENIX S.A.U.
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans
  • MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES
    Publication number: 20180318354
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS
    Publication number: 20170151284
    Abstract: The invention relates to the use of mesenchymal stromal cells (MSCs) for treating sepsis in a subject. The invention provides compositions, uses and methods for the treatment of sepsis.
    Type: Application
    Filed: June 30, 2015
    Publication date: June 1, 2017
    Applicant: TiGenix S.A.U.
    Inventors: Wilfried DALEMANS, Eleuterio LOMBARDO, Robert DEKKER
  • MESENCHYMAL STROMAL CELLS FOR TREATING RHEUMATOID ARTHRITIS
    Publication number: 20170136065
    Abstract: The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stromal cells.
    Type: Application
    Filed: June 30, 2015
    Publication date: May 18, 2017
    Applicant: TiGenix S.A.U.
    Inventors: Wilfried DALEMANS, Eleuterio LOMBARDO, Robert DEKKER
  • MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES
    Publication number: 20170119682
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES
    Publication number: 20170121685
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 4, 2017
    Inventors: Olga DE LA ROSA, Eleuterio LOMBARDO, Wilfried DALEMANS, Javier GARCÍA CASADO, Rebeca BLÁZQUEZ DURÁN, Francisco Miguel SÁNCHEZ MARGALLO,
  • LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY
    Publication number: 20160067285
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Application
    Filed: March 17, 2014
    Publication date: March 10, 2016
    Inventors: Olga DE LA ROSA, Eleuterio LOMBARDO, Wilfried DALEMANS
  • VACCINE COMPOSITION
    Publication number: 20140294935
    Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
    Type: Application
    Filed: May 12, 2014
    Publication date: October 2, 2014
    Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
  • METHODS AND COMPOSITIONS FOR USE IN INTRALYMPHATIC CELLULAR THERAPIES
    Publication number: 20140154274
    Abstract: The present invention provides medical uses and methods for the intralymphatic administration of cellular therapies. Further aspects of the invention provide compositions, kits and uses for the intralymphatic administration of cellular therapies.
    Type: Application
    Filed: January 12, 2012
    Publication date: June 5, 2014
    Applicants: TIGENIX NV, TIGENIX S.A.U.
    Inventors: Eleuterio Lombardo, Wilfried Dalemans
  • Vaccine Composition
    Publication number: 20080233154
    Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
    Type: Application
    Filed: August 25, 2006
    Publication date: September 25, 2008
    Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
  • Vaccine composition
    Publication number: 20060216307
    Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
    Type: Application
    Filed: June 9, 2006
    Publication date: September 28, 2006
    Inventors: Francois-Xavier Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
  • Vaccine
    Publication number: 20050031638
    Abstract: The present invention provides Human Papilloma Virus (HPV) fusion proteins, linked to an immunological fusion partner that provides T helper epiptopes to the HPV antigen. Vaccine formulations are provided that are useful in the treatment or Prophylaxis of HPV induced tumours.
    Type: Application
    Filed: July 27, 2004
    Publication date: February 10, 2005
    Inventors: Wilfried Dalemans, Catherine Gerard
  • Method to enhance an immune response of nucleic acid vaccination
    Publication number: 20030072768
    Abstract: This invention provides a method to enhance an immune response of nucleic acid vaccination by simultaneous administration of a polynucleotide and a polypeptide of interest.
    Type: Application
    Filed: November 12, 2002
    Publication date: April 17, 2003
    Applicant: SmithKline Beecham Biologicals, s.a.
    Inventors: Wilfried Dalemans, Marcelle Van Mechelen, Claudine Bruck, Martin Friede
  • Method to enhance an immune response of nucleic acid vaccination
    Patent number: 6500432
    Abstract: This invention provides a method to enhance an immune response of nucleic acid vaccination by simultaneous administration of a polynucleotide and a polypeptide of interest.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: December 31, 2002
    Assignee: SmithKline Beecham Biologicals, S.A.
    Inventors: Wilfried Dalemans, Marcelle Van Mechelen, Claudine Bruck, Martin Friede
  • Adenovirus-mediated transfer of genes to the lung
    Publication number: 20020164304
    Abstract: The present invention relates, in general, to a adenovirus mediated transfer of genes to the lung. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of desired genes to the lung whereby desired proteins of interest are produced for local and/or systemic use.
    Type: Application
    Filed: August 23, 2001
    Publication date: November 7, 2002
    Applicant: Transgene
    Inventors: Ronald G. Crystal, Wilfried Dalemans, Michel Perricaudet, Leslie Stratford-Perricaudet, Andrea Pavirani